Advertisement

Diagnosis of Stage IV Melanoma

  • Ahmad A. TarhiniEmail author
  • Sanjiv S. Agarwala
  • Arjun Khunger
  • Richard L. Wahl
  • Charles M. Balch
Living reference work entry

Abstract

The development of distant metastasis – stage IV disease – is associated with a dramatic decrease in the survival rate of patients who have melanoma. As seen with other tumor types, the success of treatment mainly depends on early diagnosis as well as initiation of optimal treatment. In the past decade, there has been dramatic expansion of the treatment armamentarium for patients with advanced melanoma with the development of two most important novel therapeutic strategies, immune checkpoint inhibitors and selective kinase inhibitors, which have led to significant improvement in survival and prognosis of metastatic melanoma patients. In this chapter, we provide a comprehensive overview of clinical aspects of the diagnosis of stage IV melanoma, including the timing and pattern of metastasis, clinical and imaging evaluation of distant metastases, and clinical application of biomarkers for diagnosis of metastatic melanoma. Also, various common and uncommon sites of metastasis of cutaneous melanoma are elucidated in detail.

Keywords

Melanoma Metastatic melanoma Organ-specific Radiology Biomarkers Brain metastasis 

References

  1. Abe K, Sasaki M, Kuwabara Y, Koga H, Baba S, Hayashi K, Takahashi N, Honda H (2005) Comparison of 18 FDG-PET with 99m Tc-HMDP scntigraphy for the detection of bone metastases in patients with breast cancer. Ann Nucl Med 19(7):573–579PubMedCrossRefPubMedCentralGoogle Scholar
  2. Abraham K, Reddy V, Gattuso P (1990) Neoplasms metastatic to the heart: review of 3314 consecutive autopsies. Am J Cardiovasc Pathol 3(3):195–198PubMedPubMedCentralGoogle Scholar
  3. Adrian RM, Murphy GF, Sato S, Granstein RD, Fitzpatrick TB, Sober AJ (1981) Diffuse melanosis secondary to metastatic malignant melanoma: light and electron microscopic findings. J Am Acad Dermatol 5(3):308–318PubMedCrossRefPubMedCentralGoogle Scholar
  4. Albert JG, Gimm O, Stock K, Bilkenroth U, Marsch WC, Helmbold P (2007) Small-bowel endoscopy is crucial for diagnosis of melanoma metastases to the small bowel: a case of metachronous small-bowel metastases and review of the literature. Melanoma Res 17(5):335–338PubMedCrossRefPubMedCentralGoogle Scholar
  5. Altman JF, Lowe L, Redman B, Esper P, Schwartz JL, Johnson TM, Haefner HK (2003) Placental metastasis of maternal melanoma. J Am Acad Dermatol 49(6):1150–1154PubMedCrossRefPubMedCentralGoogle Scholar
  6. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK (1978) Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42(2):660–668PubMedCrossRefPubMedCentralGoogle Scholar
  7. Amer M, Al-Sarraf M, Vaitkevicius V (1979) Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 149(5):687–692PubMedPubMedCentralGoogle Scholar
  8. Anderson JF, Kent S, Machin GA (1989) Maternal malignant melanoma with placental metastasis: a case report with literature review. Pediatr Pathol 9(1):35–42PubMedCrossRefPubMedCentralGoogle Scholar
  9. Anner RM, Drewinko B (1977) Frequency and significance of bone marrow involvement by metastatic solid tumors. Cancer 39(3):1337–1344PubMedCrossRefPubMedCentralGoogle Scholar
  10. Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A (2018) Absolute number of new lesions on 18 F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging 45(3):376–383PubMedCrossRefPubMedCentralGoogle Scholar
  11. Arora R, Robinson WA (1992) Breast metastases from malignant melanoma. J Surg Oncol 50(1):27–29PubMedCrossRefPubMedCentralGoogle Scholar
  12. Arriaga MA, Lo W, Brackmann DE (1995) Metastatic melanoma to the cerebellopontine angle. Clinical and imaging characteristics. Arch Otolaryngol Head Neck Surg 121(9):1052–1056PubMedCrossRefPubMedCentralGoogle Scholar
  13. Ashur H, Mizrahi S, Ben-Hur N, Dolberg L (1979) Metastatic malignant melanoma to the palatine tonsils: report of case. J Oral Surg (American Dental Association: 1965) 37(2):110–112Google Scholar
  14. Attia P, Phan GQ, Duray PH, Rosenberg SA (2003) Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review. Am J Clin Oncol 26(1):42PubMedPubMedCentralCrossRefGoogle Scholar
  15. Aydin A, Yu JQ, Zhuang H, Alavi A (2005) Detection of bone marrow metastases by FDG-PET and missed by bone scintigraphy in widespread melanoma. Clin Nucl Med 30(9):606–607PubMedCrossRefPubMedCentralGoogle Scholar
  16. Balch CM, Soong S-J, Murad TM, Smith JW, Maddox WA, Durant JR (1983) A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1(2):126–134PubMedCrossRefPubMedCentralGoogle Scholar
  17. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM (2000) A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88(6):1484–1491PubMedCrossRefPubMedCentralGoogle Scholar
  18. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001a) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635–3648PubMedCrossRefPubMedCentralGoogle Scholar
  19. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM (2001b) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622–3634PubMedCrossRefGoogle Scholar
  20. Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199PubMedPubMedCentralCrossRefGoogle Scholar
  21. Barker J, Girling A (1989) A case of metastatic malignant melanoma masquerading as disseminated mammary carcinoma. Histopathology 14(2):219–221PubMedCrossRefGoogle Scholar
  22. Barth A, Wanek LA, Morton DL (1995) Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181(3):193–201PubMedGoogle Scholar
  23. Basagoiti M, Vesga F, Losada J, Villanueva-Edo A (1992) Gastric metastasis of melanoma. Rev Esp Enferm Dig 82(6):419–421PubMedGoogle Scholar
  24. Basu D, Bhade BA, Ghotekar L, Mathew T, Dutta T (2002) Malignant melanoma metastatic to bone marrow. Indian J Pathol Microbiol 45(1):107–109PubMedGoogle Scholar
  25. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, Delpero JR, Birmbaum D, Hassoun J, Bonerandi JJ (1995) Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Archives of dermatology 131(4):443–447PubMedCrossRefGoogle Scholar
  26. Bauer RD, McCoy CP, Roberts DK, Fritz G (1984) Malignant melanoma metastatic to the endometrium. Obstet Gynecol 63(2):264–268PubMedGoogle Scholar
  27. Bedikian AY, Wei C, Detry M, Kim KB, Papadopoulos NE, Hwu W-J, Homsi J, Davies M, McIntyre S, Hwu P (2011) Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol 34(6):603–610PubMedCrossRefGoogle Scholar
  28. Berking C, Schlüpen EM, Schrader A, Atzpodien J, Volkenandt M (1999) Tumor markers in peripheral blood of patients with malignant melanoma: multimarker RT-PCR versus a luminoimmunometric assay for S-100. Arch Dermatol Res 291(9):479–484PubMedCrossRefGoogle Scholar
  29. Berry N, Reese L (1953) Malignant melanoma which had its first clinical manifestations in the prostate gland. J Urol 69(2):286–290PubMedCrossRefPubMedCentralGoogle Scholar
  30. Blochin E, Nonaka D (2009) Diagnostic value of Sox10 immunohistochemical staining for the detection of metastatic melanoma in sentinel lymph nodes. Histopathology 55(5):626–628PubMedCrossRefPubMedCentralGoogle Scholar
  31. Bognel C, Lasser P, Zimmermann P (1992) Gastric metastases. Apropos of 17 cases. Ann Chir 5:436–441Google Scholar
  32. Böhm M, Schiller M, Nashan D, Stadler R, Luger TA, Metze D (2001) Diffuse melanosis arising from metastatic melanoma: pathogenetic function of elevated melanocyte peptide growth factors. J Am Acad Dermatol 44(5):747–754PubMedCrossRefPubMedCentralGoogle Scholar
  33. Bonfrer JM, Korse CM (2001) Monitoring malignant melanoma with the S-100B tumour marker. Recent Results Cancer Res 158:149–157PubMedCrossRefPubMedCentralGoogle Scholar
  34. Bonfrer J, Korse C, Nieweg O, Rankin E (1998) The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer 77(12):2210PubMedPubMedCentralCrossRefGoogle Scholar
  35. Booth JB (1965) Malignant melanoma of the stomach: report of a case presenting as an acute perforation and review of the literature. Br J Surg 52(4):262–270PubMedCrossRefPubMedCentralGoogle Scholar
  36. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, Stolz W, Buettner R (1997) Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 57(15):3149–3153PubMedPubMedCentralGoogle Scholar
  37. Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon D (1998) Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol 16(8):2632–2640PubMedCrossRefPubMedCentralGoogle Scholar
  38. Boughan KM, Setrakian S, Lee CH, Spiro TP, Daw HA (2009) A renal mass in a patient with melanoma. Clin Genitourin Cancer 7(3):E98–E100PubMedCrossRefPubMedCentralGoogle Scholar
  39. Bowman CB, Guber D, Brown CH, Curtin VT (1994) Cutaneous malignant melanoma with diffuse intraocular metastases. Arch Ophthalmol 112(9):1213–1216PubMedCrossRefPubMedCentralGoogle Scholar
  40. Bozbora A, Barbaros U, Kaya H, Erbil Y, Kapran Y, Özbey N, Özarmagan S (2005) Thyroid metastasis of malignant melanoma. Am J Clin Oncol 28(6):642–643PubMedCrossRefPubMedCentralGoogle Scholar
  41. Braman SS, Whitcomb ME (1975) Endobronchial metastasis. Arch Intern Med 135(4):543–547PubMedCrossRefPubMedCentralGoogle Scholar
  42. Breazzano MP, Barker-Griffith AE (2016) Features of cutaneous malignant melanoma metastatic to the retina and vitreous. Ocul Oncol Pathol 2(2):80–85CrossRefGoogle Scholar
  43. Bremer AM, West CR, Didolkar MS (1978) An evaluation of the surgical management of melanoma of the brain. J Surg Oncol 10(3):211–219PubMedCrossRefPubMedCentralGoogle Scholar
  44. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C, Möhler T, Hunstein W (1993) Hematogenous spread of malignant melanoma cells in different stages of disease. J Investig Dermatol 101(6):887–889PubMedCrossRefPubMedCentralGoogle Scholar
  45. Brossart P, Schmier J-W, Krüger S, Willhauck M, Scheibenbogen C, Möhler T, Keilholz U (1995) A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res 55(18):4065–4068PubMedPubMedCentralGoogle Scholar
  46. Budman DR, Camacho E, Wittes RE (1978) The current causes of death in patients with malignant melanoma. Eur J Cancer (1965) 14(4):327–330CrossRefGoogle Scholar
  47. Bullard D, Cox E, Seigler H (1981) Central nervous system metastases in malignant melanoma. Neurosurgery 8(1):26–30PubMedCrossRefPubMedCentralGoogle Scholar
  48. Busam KJ, Chen Y-T, Old LJ, Stockert E, Iversen K, Coplan KA, Rosai J, Barnhill RL, Jungbluth AA (1998) Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol 22(8):976–982PubMedCrossRefPubMedCentralGoogle Scholar
  49. Butte JM, Meneses M, Waugh E, Parada H, De La Fuente H (2009) Ileal intussusception secondary to small bowel metastases from melanoma. Am J Surg 198(1):e1–e2PubMedCrossRefPubMedCentralGoogle Scholar
  50. Buzbee TM, Legha SS (1992) Spontaneous rupture of spleen in a patient with splenic metastasis of melanoma. A case report. Tumori J 78(1):47–48CrossRefGoogle Scholar
  51. Caron J, Mangé A, Guillot B, Solassol J (2009) Highly sensitive detection of melanoma based on serum proteomic profiling. J Cancer Res Clin Oncol 135(9):1257–1264PubMedCrossRefPubMedCentralGoogle Scholar
  52. Casey JH, Shapiro RF (1974) Metastatic melanoma presenting as primary uterine neoplasm: a case report. Cancer 33(3):729–731PubMedCrossRefPubMedCentralGoogle Scholar
  53. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M (2007) Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology 69(4):637–641PubMedCrossRefPubMedCentralGoogle Scholar
  54. Cavanna L, Lazzaro A, Vallisa D, Civardi G, Artioli F (2007) Role of image-guided fine-needle aspiration biopsy in the management of patients with splenic metastasis. World J Surg Oncol 5(1):13PubMedPubMedCentralCrossRefGoogle Scholar
  55. Chamberlain D (1966) Malignant melanoma, metastatic to the larynx. Arch Otolaryngol 83(3):231–232PubMedCrossRefPubMedCentralGoogle Scholar
  56. Chamberlain MC, Sandy AD, Press GA (1990) Leptomeningeal metastasis A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 40(3 Part 1):435–435PubMedCrossRefPubMedCentralGoogle Scholar
  57. Chaudhary S, Bansal C, Husain A (2013) Literature meta-analysis of zosteriform cutaneous metastases from melanoma and a clinico-histopathological report from India. ecancermedicalscience 7:324PubMedPubMedCentralGoogle Scholar
  58. Cho SY, Lipson EJ, Im H-J, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL (2017) Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med 58(9):1421PubMedPubMedCentralCrossRefGoogle Scholar
  59. Chung MH, Gupta RK, Essner R, Ye W, Yee R, Morton DL (2002) Serum TA90 immune complex assay can predict outcome after resection of thick (≥ 4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol 9(2):120–126PubMedPubMedCentralGoogle Scholar
  60. Clark PB, Soo V, Kraas J, Shen P, Levine EA (2006) Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 141(3):284–288PubMedCrossRefPubMedCentralGoogle Scholar
  61. Cochran AJ, Wen DR, Herschman HR, Gaynor RB (1982) Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 30(3):295–297PubMedCrossRefPubMedCentralGoogle Scholar
  62. Cochran A, Lu H, Li P, Saxton R, Wen D (1993) S-100 protein remains a practical marker for melanocytic and other tumours. Melanoma Res 3(5):325–330PubMedCrossRefPubMedCentralGoogle Scholar
  63. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Ernstoff M, Fields RC (2016) Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 14(4):450–473CrossRefGoogle Scholar
  64. Compérat E, Bardier-Dupas A, Camparo P, Capron F, Charlotte F (2007) Splenic metastases: clinicopathologic presentation, differential diagnosis, and pathogenesis. Arch Pathol Lab Med 131(6):965–969PubMedPubMedCentralGoogle Scholar
  65. Crippa F, Leutner M, Belli F, Gallino F (2000) Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 41(9):1491PubMedPubMedCentralGoogle Scholar
  66. Crowley NJ, Seigler HF (1990) Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 212(2):173–177PubMedPubMedCentralCrossRefGoogle Scholar
  67. Daimaru Y, Hashimoto H, Enjoji M (1985) Malignant peripheral nerve-sheath tumors (malignant schwannomas). An immunohistochemical study of 29 cases. Am J Surg Pathol 9(6):434–444PubMedCrossRefPubMedCentralGoogle Scholar
  68. Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H, Schober O, Rummeny EJ (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol 177(1):229–236CrossRefGoogle Scholar
  69. Damian D, Fulham M, Thompson E, Thompson J (1996) Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 6(4):325–329PubMedCrossRefPubMedCentralGoogle Scholar
  70. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687–1696PubMedCrossRefPubMedCentralGoogle Scholar
  71. de Bustros S, Augsburger JJ, Shields JA, Shakin EP, Pryor CC (1985) Intraocular metastases from cutaneous malignant melanoma. Arch Ophthalmol 103(7):937–940PubMedCrossRefPubMedCentralGoogle Scholar
  72. de la Monte SM, Moore GW, Hutchins GM (1983) Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 43(7):3427–3433PubMedPubMedCentralGoogle Scholar
  73. De Palma GD, Masone S, Rega M, Simeoli I, Donisi M, Addeo P, Iannone L, Pilone V, Persico G (2006) Metastatic tumors to the stomach: clinical and endoscopic features. World J Gastroenterol 12(45):7326PubMedPubMedCentralCrossRefGoogle Scholar
  74. De Roeck L, Wuyts L, Peters B, Ruppert M (2017) 5-Year survival after splenectomy in a patient with recurrent cutaneous melanoma: a case report. Acta Chir Belg 118:384–387PubMedCrossRefPubMedCentralGoogle Scholar
  75. Deichmann M, Benner A, Bock M, Jäckel A, Uhl K, Waldmann V, Näher H (1999) S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 17(6):1891–1896PubMedCrossRefPubMedCentralGoogle Scholar
  76. Den Uil SH, Thomassen I, Vermeulen EG, Vuylsteke RJ, Stockmann HB, de Vries M (2014) Small bowel perforation caused by advanced melanoma. Tumori J 100(4):e140–e143CrossRefGoogle Scholar
  77. Devereux D, Johnston G, Blei L, Head G, Makuch R, Burt M (1980) The role of bone scans in assessing malignant melanoma in patients with stage III disease. Surg Gynecol Obstet 151(1):45–48PubMedPubMedCentralGoogle Scholar
  78. Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S, Martín-Algarra S, González A (2011) Evaluation of multiple serum markers in advanced melanoma. Tumor Biol 32(6):1155CrossRefGoogle Scholar
  79. Dietlein M, Krug B, Groth W, Smolarz K, Scheidhauer K, Psaras T, Stützer H, Lackner K, Schicha H (1999) Positron emission tomography using 18F-fluorodeoxyglucose in advanced stages of malignant melanoma: a comparison of ultrasonographic and radiological methods of diagnosis. Nucl Med Commun 20(3):255–261PubMedCrossRefPubMedCentralGoogle Scholar
  80. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Bröcker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5(1):67–68PubMedCrossRefPubMedCentralGoogle Scholar
  81. Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A (2012) Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer 48(5):695–702PubMedCrossRefPubMedCentralGoogle Scholar
  82. Eide N, Syrdalen P (1990) Intraocular metastasis from cutaneous malignant melanoma. Acta Ophthalmol 68(1):102–106CrossRefGoogle Scholar
  83. Eigentler TK, Figl A, Krex D, Mohr P, Mauch C, Rass K, Bostroem A, Heese O, Koelbl O, Garbe C (2011) Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer 117(8):1697–1703PubMedCrossRefPubMedCentralGoogle Scholar
  84. Einhorn LH, Burgess MA, Vallejos C, Bodey GP, Gutterman J, Mavligit G, Hersh EM, Luce JK, Frei E, Freireich EJ (1974) Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 34(8):1995–2004PubMedPubMedCentralGoogle Scholar
  85. Emmot WW, Vacek JL, Agee K, Moran J, Dunn MI (1987) Metastatic malignant melanoma presenting clinically as obstruction of the right ventricular inflow and outflow tracts: characterization by magnetic resonance imaging. Chest 92(2):362–364PubMedCrossRefPubMedCentralGoogle Scholar
  86. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS (1998) Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16(3):1103–1111PubMedCrossRefPubMedCentralGoogle Scholar
  87. Evans R, Bland K, McMurtrey M, Ballantyne A (1980) Radionuclide scans not indicated for clinical stage I melanoma. Surg Gynecol Obstet 150(4):532–534PubMedPubMedCentralGoogle Scholar
  88. Ewend MG, Carey LA, Brem H (1996) Treatment of melanoma metastases in the brain. In: Seminars in surgical oncology, vol 6. Wiley Online Library, New York, pp 429–435Google Scholar
  89. Falk MS, Truitt AK, Coakley FV, Kashani-Sabet M, Hawkins RA, Franc B (2007) Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma. Nucl Med Commun 28(4):273–280PubMedCrossRefPubMedCentralGoogle Scholar
  90. Fambrini M, Andersson KL, Buccoliero AM, Pieralli A, Livi L, Marchionni M (2008) Late solitary metastasis of cutaneous malignant melanoma presenting as abnormal uterine bleeding. J Obstet Gynaecol Res 34(4 pt 2):731–734PubMedCrossRefPubMedCentralGoogle Scholar
  91. Faries MB, Gupta RK, Ye X, Lee C, Yee R, Leopoldo Z, Essner R, Foshag LJ, Elashoff D, Morton DL (2007) A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients. Cancer Investig 25(5):285–293CrossRefGoogle Scholar
  92. Faries MB, Steen S, Ye X, Sim M, Morton DL (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217(1):27–34PubMedPubMedCentralCrossRefGoogle Scholar
  93. Fawaz F, Hill GJ (1983) Adult intussusception due to metastatic tumors. South Med J 76(4):522PubMedCrossRefPubMedCentralGoogle Scholar
  94. Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008) S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients. Melanoma Res 18(2):134–140PubMedCrossRefPubMedCentralGoogle Scholar
  95. Feldman L, Kricun ME (1979) Malignant melanoma presenting as a mediastinal mass. JAMA 241(4):396–397PubMedCrossRefPubMedCentralGoogle Scholar
  96. Felix EL, Bagley DH, Sindelar WF, Johnston GS, Ketcham AS (1976) The value of the liver scan in preoperative screening of patients with malignancies. Cancer 38(3):1137–1141PubMedCrossRefPubMedCentralGoogle Scholar
  97. Ferlito A, Caruso G, Recher G (1988) Secondary laryngeal tumors: report of seven cases with review of the literature. Arch Otolaryngol Head Neck Surg 114(6):635–639PubMedCrossRefPubMedCentralGoogle Scholar
  98. Feron O (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92(3):329–333.  https://doi.org/10.1016/j.radonc.2009.06.025CrossRefPubMedPubMedCentralGoogle Scholar
  99. Fife K, Colman M, Stevens G, Firth I, Moon D, Shannon K, Harman R, Petersen-Schaefer K, Zacest A, Besser M (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22(7):1293–1300PubMedCrossRefPubMedCentralGoogle Scholar
  100. Finck S, Giuliano A, Morton D (1983) LDH and melanoma. Cancer 51(5):840–843PubMedCrossRefPubMedCentralGoogle Scholar
  101. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S (2009) Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 27(13):2199–2208PubMedCrossRefPubMedCentralGoogle Scholar
  102. Fitzgibbons PL, Martin SE, Simmons TJ (1987) Malignant melanoma metastatic to the ovary. Am J Surg Pathol 11(12):959–964PubMedCrossRefGoogle Scholar
  103. Flipse TR, Tazelaar HD, Holmes DR (1990) Diagnosis of malignant cardiac disease by endomyocardial biopsy. Mayo Clin Proc 11:1415–1422. ElsevierCrossRefGoogle Scholar
  104. Fogarty G, Tartaglia C (2006) The utility of magnetic resonance imaging in the detection of brain metastases in the staging of cutaneous melanoma. Clin Oncol 18(4):360–362CrossRefGoogle Scholar
  105. Fon GT, Wong W, Gold R, Kaiser L (1981) Skeletal metastases of melanoma: radiographic, scintigraphic, and clinical review. Am J Roentgenol 137(1):103–108CrossRefGoogle Scholar
  106. Font RL, Naumann G, Zimmerman LE (1967) Primary malignant melanoma of the skin metastatic to the eye and orbit: report of ten cases and review of the literature. Am J Ophthalmol 63(4):738–754PubMedCrossRefPubMedCentralGoogle Scholar
  107. Forschner A, Olthof S-C, Gückel B, Martus P, Vach W, la Fougère C, Nikolaou K, Keim U, Eigentler TK, Garbe C (2017) Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. Eur J Nucl Med Mol Imaging 44(8):1312–1318PubMedCrossRefPubMedCentralGoogle Scholar
  108. Foss A, Guille M, Occleston N, Hykin P, Hungerford J, Lightman S (1995) The detection of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction. Br J Cancer 72(1):155PubMedPubMedCentralCrossRefGoogle Scholar
  109. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, Volkenandt M, Ganser A, Atzpodien J (1998) Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer 78(1):40–45PubMedPubMedCentralCrossRefGoogle Scholar
  110. Fraser-Moodie A, Hughes R, Jones S, Shorey B, Snape L (1976) Malignant melanoma metastases to the alimentary tract. Gut 17(3):206–209PubMedPubMedCentralCrossRefGoogle Scholar
  111. Freedman WL, McMahon FJ (1960) Placental metastasis: review of the literature and report of a case of metastatic melanoma. Obstet Gynecol 16(5):550–560PubMedGoogle Scholar
  112. Freeland A, Van Nostrand A, Jahn A (1979) Metastases to the larynx. J Otolaryngol 8(5):448–456PubMedGoogle Scholar
  113. Friedman KP, Wahl RL (2004) Clinical use of positron emission tomography in the management of cutaneous melanoma. In: Seminars in nuclear medicine, vol 4. Elsevier, New York, pp 242–253Google Scholar
  114. Fulciniti F, Losito S, Botti G, Di Mattia D, La Mura A, Pisano C, Pignata S (2007) Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years. Ann Oncol 19(4):682–687PubMedCrossRefGoogle Scholar
  115. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B (2003) Diagnostic value and prognostic significance of protein S-100β, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 97(7):1737–1745PubMedCrossRefGoogle Scholar
  116. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Reinhold U, Kortmann R-D, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R (2007) Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17(6):393–399PubMedCrossRefGoogle Scholar
  117. Gaudy-Marqueste C, Dussouil A, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard M, Régis J (2017) Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer 84:44–54PubMedCrossRefGoogle Scholar
  118. Gaviani P, Mullins M, Braga T, Hedley-Whyte E, Halpern EF, Schaefer P, Henson J (2006) Improved detection of metastatic melanoma by T2∗-weighted imaging. Am J Neuroradiol 27(3):605–608PubMedGoogle Scholar
  119. Gelberman RH, Stewart WR, Harrelson JM (1978) Hand metastasis from melanoma: a case study. Clin Orthop Relat Res 136:264–266Google Scholar
  120. Gershenwald JE, Balch CM, Soong SJ, Thompson JF (2003) Prog­nostic factors and natural history. In: Balch CM, Houghton AN, Sober SJ, Soong SJ (eds) Cutaneous melanoma, 4th edn. Quality Medical Publishing, St LouisGoogle Scholar
  121. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel, the International Melanoma Database, Discovery Platform (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472–492.  https://doi.org/10.3322/caac.21409CrossRefPubMedPubMedCentralGoogle Scholar
  122. Gibbons JA, Devig PM (1978) Massive hemothorax due to metastatic malignant melanoma. Chest 73(1):123PubMedCrossRefGoogle Scholar
  123. Gibson LE, Goellner JR (1988) Amelanotic melanoma: cases studied by Fontana stain, S-100 immunostain, and ultrastructural examination. Mayo Clin Proc 8:777–782. ElsevierCrossRefGoogle Scholar
  124. Ginaldi S, Wallace S, Shalen P, Luna M, Handel S (1981) Cranial computed tomography of malignant melanoma. Am J Roentgenol 136(1):145–149CrossRefGoogle Scholar
  125. Gindea AJ, Steele P, Rumancik WM, Culubret M, Feiner H, Sanger JJ, Kronzon I (1987) Biventricular cavity obliteration by metastatic malignant melanoma: role of magnetic resonance imaging in the diagnosis. Am Heart J 114(5):1249–1253PubMedCrossRefGoogle Scholar
  126. Glancy DL, Roberts WC (1968) The heart in malignant melanoma: a study of 70 autopsy cases. Am J Cardiol 21(4):555–571PubMedCrossRefGoogle Scholar
  127. Gläser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W (1997) Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol 15(8):2818–2825PubMedCrossRefGoogle Scholar
  128. Gokaslan Z, Aladag M, Ellerhorst J (2000) Melanoma metastatic to the spine: a review of 133 cases. Melanoma Res 10:78–80PubMedCrossRefGoogle Scholar
  129. Gold JS, Jaques DP, Busam KJ, Brady MS, Coit DG (2007) Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 14(7):2133–2140PubMedCrossRefGoogle Scholar
  130. Goldman S, Pollak E, Wolfman E Jr (1977a) Massive upper gastrointestinal bleeding during chemotherapy for malignant melanoma. Am Surg 43(11):768PubMedGoogle Scholar
  131. Goldman SL, Pollak EW, Wolfman EF (1977b) Gastric ulcer: an unusual presentation of malignant melanoma. JAMA 237(1):52–52PubMedCrossRefGoogle Scholar
  132. Goldstein HM, Kaminsky S, Wallace S, Johnson DE (1974) Urographic manifestations of metastatic melanoma. Am J Roentgenol 121(4):801–805CrossRefGoogle Scholar
  133. Goldstein H, Beydoun M, Dodd G (1977) Radiologic spectrum of melanoma metastatic to the gastrointestinal tract. Am J Roentgenol 129(4):605–612CrossRefGoogle Scholar
  134. Gonzalez MS, Hammond DO (1983) Malignant melanoma in the ovary with ultrastructural confirmation. Am J Obstet Gynecol 147(6):722–724PubMedCrossRefGoogle Scholar
  135. Goodman P, Karakousis C (1981) Symptomatic gastrointestinal metastases from malignant melanoma. Cancer 48(4):1058–1059PubMedCrossRefGoogle Scholar
  136. Görg C, Hoffmann A (2008) Metastases to the spleen in 59 cancer patients: a 14-year clinicosonographic study. Ultraschall Med (Stuttgart, Germany: 1980) 29(2):173–178CrossRefGoogle Scholar
  137. Gown AM, Vogel AM (1985) Monoclonal antibodies to human intermediate filament proteins: III. Analysis of tumors. Am J Clin Pathol 84(4):413–424PubMedCrossRefGoogle Scholar
  138. Griffeth LK, Rich KM, Dehdashti F, Simpson JR, Fusselman M, McGuire A, Siegel B (1993) Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 186(1):37–44PubMedCrossRefGoogle Scholar
  139. Gritters LS, Francis IR, Zasadny KR, Wahi RL (1993) Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2. The Journal of Nuclear Medicine 34:1420PubMedGoogle Scholar
  140. Gupta TD, Brasfield R (1964a) Metastatic melanoma. A clinicopathological study. Cancer 17(10):1323–1339CrossRefGoogle Scholar
  141. Gupta TD, Brasfield RD (1964b) Metastatic melanoma of the gastrointestinal tract. Arch Surg 88(6):969–973CrossRefGoogle Scholar
  142. Gupta RK, Morton DL (1992) Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 6(5):329–336PubMedCrossRefGoogle Scholar
  143. Gutfreund CA, Moore D, Surg OHN (1995) Metastatic melanoma to the pharynx and trachea. Otolaryngol Head Neck Surg 113(6):820–821PubMedCrossRefGoogle Scholar
  144. Habek D, Marton I, Bauman R, Prka M, Bobić MV (2012) Ruptured ovarian metastatic malignant melanoma caused acute abdomen. Central Eur J Med 7(2):241–244Google Scholar
  145. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca RS, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Jensen E, Ibrahim N, Ahsan S, Ribas A (2018) 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. J Clin Oncol 36(suppl):abstr 9516. ASCO annual meeting, 2018CrossRefGoogle Scholar
  146. Hanash KA, Carney JA, Kelalis PP (1969) Metastatic tumors to testicles: routes of metastasis. J Urol 102(4):465–468PubMedCrossRefGoogle Scholar
  147. Harpole JD, Johnson C, Wolfe W, George S, Seigler H (1992) Analysis of 945 cases of pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 103(4):743–748;discussion 748-750PubMedGoogle Scholar
  148. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E (1999a) Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 140(6):1065–1071PubMedCrossRefGoogle Scholar
  149. Hauschild A, Engel G, Brenner W, Gläser R, Mönig H, Henze E, Christophers E (1999b) S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56(4):338–344PubMedCrossRefGoogle Scholar
  150. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Gläser R, Henze E, Christophers E (1999c) Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 9(2):155–161PubMedCrossRefGoogle Scholar
  151. Henderson LT, Robbins M, Weitzner S (1986) Disseminated malignant melanoma. Arch Otolaryngol Head Neck Surg 112:659–663PubMedCrossRefGoogle Scholar
  152. Herrera GA, Turbat-Herrera EA, Lott RL (1988) S-100 protein expression by primary and metastatic adenocarcinomas. Am J Clin Pathol 89(2):168–176PubMedCrossRefGoogle Scholar
  153. Hirst LW, Reich J, Galbraith J (1979) Primary cutaneous malignant melanoma metastatic to the iris. Br J Ophthalmol 63(3):165–168PubMedPubMedCentralCrossRefGoogle Scholar
  154. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL (1998) Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227(5):764PubMedPubMedCentralCrossRefGoogle Scholar
  155. Holtkamp LH, Read RL, Emmett L, Thompson JF, Nieweg OE (2017) Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma Res 27(5):457–462PubMedCrossRefGoogle Scholar
  156. Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL (1998) Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 187(2):191–197PubMedCrossRefGoogle Scholar
  157. Hulick P (1995) Brain metastases as the presenting manifestation of malignant melanoma. A case report. Del Med J 67(4):231–234PubMedGoogle Scholar
  158. Ihle MA, Fassunke J, König K, Grünewald I, Schlaak M, Kreuzberg N, Tietze L, Schildhaus H-U, Büttner R, Merkelbach-Bruse S (2014) Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p. V600E BRAF mutations. BMC Cancer 14(1):13PubMedPubMedCentralCrossRefGoogle Scholar
  159. Itakura E, Huang R-R, Wen D-R, Paul E, Wünsch PH, Cochran AJ (2008) RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi. Mod Pathol 21(3):326PubMedCrossRefGoogle Scholar
  160. Itakura E, Huang R-R, Wen D-R, Paul E, Wünsch PH, Cochran AJ (2011) IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol 24(6):801PubMedPubMedCentralCrossRefGoogle Scholar
  161. Itin PH, Lautenschlager S, Buechner SA (1995) Zosteriform metastases in melanoma. J Am Acad Dermatol 32(5):854–857PubMedCrossRefGoogle Scholar
  162. Jaffer S, Zakowski M (2002) Fine-needle aspiration biopsy of axillary lymph nodes. Diagn Cytopathol 26(2):69–74PubMedCrossRefGoogle Scholar
  163. Jaffrey I, Lefkowitz L, Lestch S, Weiss D (1976) Metastatic melanoma presenting as abnormal uterine bleeding: A case report. Mount Sinai J Med, New York 43(2):180Google Scholar
  164. Jain D, Kumar N, Daga MK (2007) Metastatic malignant melanoma in bone marrow with occult primary site–a case report with review of literature. Diagn Pathol 2(1):38PubMedPubMedCentralCrossRefGoogle Scholar
  165. Jennings C, Kim J (2011) Identification of nodal metastases in melanoma using sox-10. Am J Dermatopathol 33(5):474–482PubMedCrossRefGoogle Scholar
  166. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 15(2):194–202PubMedCrossRefGoogle Scholar
  167. Johnson DE, Jackson L, Ayala A (1971) Secondary carcinoma of the testis. South Med J 64(9):1128PubMedCrossRefGoogle Scholar
  168. Joseph RW, Elassaiss-Schaap J, Kefford RF, Hwu WJ, Wolchok JD, Joshua AM, Ribas A, Hodi FS, Hamid O, Robert C, Daud AI, Dronca RS, Hersey P, Weber JS, Patnaik A, de Alwis DP, Perrone AM, Zhang J, Kang SP, Ebbinghaus SW, Anderson KM, Gangadhar T (2018) Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res.  https://doi.org/10.1158/1078-0432.CCR-17-2386
  169. Jr SC, Dodge RK, Stanley WE, Seigler HF (1992) The annual risk of melanoma progression. Implications for the concept of cure. Cancer 70(7):1917CrossRefGoogle Scholar
  170. Jundt G, Schulz A, Paul E, Cochran A, Herschman H (1986) S-100 protein in amelanotic melanoma. A convenient immunocytochemical approach compared to electron microscopy. Pathol Res Pract 181(1):37–44PubMedCrossRefGoogle Scholar
  171. Jungbluth AA, Busam KJ, Gerald WL, Stockert E, Coplan KA, Iversen K, MacGregor DP, Old LJ, Chen Y-T (1998) A103: an anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol 22(5):595–602PubMedCrossRefGoogle Scholar
  172. Jungbluth A, Iversen K, Coplan K, Williamson B, Chen Y-T, Stockert E, Old LJ, Busam KJ (1999) Expression of melanocyte-associated markers gp-100 and Melan-A/MART-1 in angiomyolipomas. Virchows Arch 434(5):429–435PubMedCrossRefGoogle Scholar
  173. Kamaya A, Weinstein S, Desser TS (2006) Multiple lesions of the spleen: differential diagnosis of cystic and solid lesions. In: Seminars in ultrasound, CT and MRI, vol 27, No. 5, WB Saunders, pp 389–403Google Scholar
  174. Karakousis C, Holyoke ED, Douglass HO (1974) Intussusception as a complication of malignant neoplasm. Arch Surg 109(4):515–518PubMedCrossRefGoogle Scholar
  175. Karakousis C, Temple D, Moore R, Ambrus J (1983) Prognostic parameters in recurrent malignant melanoma. Cancer 52(3):575–579PubMedCrossRefPubMedCentralGoogle Scholar
  176. Karjalainen JM (2001) Transcription factors and other dysregulated proteins in melanoma prognosis. Curr Oncol Rep 3(4):368–375PubMedCrossRefPubMedCentralGoogle Scholar
  177. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B (1998) Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16(9):2921–2929PubMedCrossRefPubMedCentralGoogle Scholar
  178. Keilholz U, Martus P, Punt CJA, Kruit W, Mooser G, Schadendorf D, Liénard D, Dummer R, Koller J, Voit C, Eggermont AMM (2002) Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer (Oxford, England: 1990) 38(11):1501–1511CrossRefGoogle Scholar
  179. Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JWB, Soetekouw P, Jansen RL (2014) Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 63(5):449–458PubMedPubMedCentralGoogle Scholar
  180. Kelley MC, Jones RC, Gupta RK, Yee R, Stern S, Wanek L, Morton DL (1998) Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer 83(7):1355–1361PubMedCrossRefPubMedCentralGoogle Scholar
  181. Kelley MC, Gupta RK, Hsueh EC, Yee R, Stern S, Morton DL (2001) Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma. J Clin Oncol 19(4):1176–1182PubMedCrossRefPubMedCentralGoogle Scholar
  182. Kern KA (1991) [14C] deoxyglucose uptake and imaging in malignant melanoma. J Surg Res 50(6):643–647PubMedCrossRefPubMedCentralGoogle Scholar
  183. Khoddami M (1993) Cytologic diagnosis of metastatic malignant melanoma of the lung in sputum and bronchial washings. A case report. Acta Cytol 37(3):403–408PubMedPubMedCentralGoogle Scholar
  184. Kim J-W, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66(18):8927–8930PubMedCrossRefPubMedCentralGoogle Scholar
  185. Kingdom TT, Lalwani AK, Pitts LH (1993) Isolated metastatic melanoma of the cerebellopontine angle: case report. Neurosurgery 33(1):142–144PubMedPubMedCentralGoogle Scholar
  186. Klausner J, Skornick Y, Lelcuk S, Baratz M, Merhav A (1982) Acute complications of metastatic melanoma to the gastrointestinal tract. Br J Surg 69(4):195–196PubMedCrossRefPubMedCentralGoogle Scholar
  187. Konrad K, Wolff K (1974) Pathogenesis of diffuse melanosis secondary to malignant melanoma. Br J Dermatol 91(6):635–655PubMedCrossRefPubMedCentralGoogle Scholar
  188. Konstadoulakis M, Messaris E, Zografos G, Androulakis G (2000) Prognostic factors in malignant melanoma patients with solitary or multiple brain metastases: is there a role for surgery? J Neurosurg Sci 44(4):211PubMedPubMedCentralGoogle Scholar
  189. Krogh M, Christensen I, Bouwhuis M, Johansen J, Schmidt H, Hansson J, Aamdal S, Testori A, Eggermont A, Bastholt L (2010) Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. J Clin Oncol 28(15_suppl):8587–8587CrossRefGoogle Scholar
  190. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, Kirchner H, Schluepen EM, Volkenandt M, Ganser A (1996) Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. JNCI: J Natl Cancer Inst 88(9):590–594PubMedCrossRefPubMedCentralGoogle Scholar
  191. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242(3):647–649PubMedCrossRefPubMedCentralGoogle Scholar
  192. Kutalek SP, Panidis IP, Kotler MN, Mintz GS, Carver J, Ross JJ (1985) Metastatic tumors of the heart detected by two-dimensional echocardiography. Am Heart J 109(2):343–349PubMedCrossRefPubMedCentralGoogle Scholar
  193. Lam KY, Lo CY (2002) Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 56(1):95–101CrossRefGoogle Scholar
  194. Larsen AK, Krag C, Geertsen P, Jakobsen LP (2013) Isolated malignant melanoma metastasis to the pancreas. Plast Reconstr Surg Glob Open 1(8):e74PubMedPubMedCentralCrossRefGoogle Scholar
  195. Lau Y, Sabokbar A, Giele H, Cerundolo V, Hofstetter W, Athanasou N (2006) Malignant melanoma and bone resorption. Br J Cancer 94(10):1496PubMedPubMedCentralCrossRefGoogle Scholar
  196. Lee YTNM (1980) Malignant melanoma: pattern of metastasis. CA Cancer J Clin 30(3):137–142PubMedCrossRefPubMedCentralGoogle Scholar
  197. Lee AH (2007) The histological diagnosis of metastases to the breast from extramammary malignancies. J Clin Pathol 60(12):1333–1341PubMedPubMedCentralCrossRefGoogle Scholar
  198. Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn JA, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R (2018) Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma. Ann Oncol 29(2):490–496.  https://doi.org/10.1093/annonc/mdx717CrossRefPubMedPubMedCentralGoogle Scholar
  199. Lerner A, Moellmann G (1993) Two rare manifestations of melanomas: generalized cutaneous melanosis and rapid solar induction of showers of small pigmented lesions. A critical review of the literature and presentation of two additional cases. Acta Derm Venereol 73(4):241–250PubMedPubMedCentralGoogle Scholar
  200. Les Cole E, Zakov ZN, Meisler DM, Tuthill RJ, McMahon JT (1986) Cutaneous malignant melanoma metastatic to the vitreous. Arch Ophthalmol 104(1):98–101CrossRefGoogle Scholar
  201. Lesur G, Bergemer A, Metges J, Barre O, Dupuy P, Le JP (1992) The metastatic liver: a rare cause of hepatocellular insufficiency. Ann Gastroenterol Hepatol 5:217–220Google Scholar
  202. Levitt R, Koehler R, Sagel S, Lee JK (1982) Metastatic disease of the mesentery and omentum. Radiol Clin N Am 20(3):501–510PubMedPubMedCentralGoogle Scholar
  203. Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D (2018) Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol 29:1569PubMedCrossRefPubMedCentralGoogle Scholar
  204. Liang KV, Sanderson SO, Nowakowski GS, Arora AS (2006) Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 4:511–516. ElsevierCrossRefGoogle Scholar
  205. Licciardello M, Giura M, Rozzo G, Marra E, Fava P, Astrua C, Contu V, Lista P, Fierro M, Quaglino P (2017) Arrhythmias in a patient with metastatic melanoma treated with targeted therapy and implantable cardioverter defibrillator. Br J Dermatol 177(2):584–587PubMedCrossRefPubMedCentralGoogle Scholar
  206. Lo SN, Scolyer RA, Thompson JF (2018) Long-term survival of patients with thin (T1) cutaneous melanomas: a Breslow thickness cut point of 0.8 mm separates higher-risk and lower-risk tumors. Ann Surg Oncol 25(4):894–902PubMedCrossRefPubMedCentralGoogle Scholar
  207. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA (2013) Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 37(1):61–65.  https://doi.org/10.1097/PAS.0b013e31826485c0CrossRefPubMedPubMedCentralGoogle Scholar
  208. Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA (2016) Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 17(12):1743–1754.  https://doi.org/10.1016/S1470-2045(16)30578-2CrossRefPubMedPubMedCentralGoogle Scholar
  209. Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT (2018) Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 36(7):667–673.  https://doi.org/10.1200/JCO.2017.74.1025CrossRefPubMedPubMedCentralGoogle Scholar
  210. Lookingbill DP, Spangler N, Helm KF (1993) Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 29(2):228–236PubMedCrossRefPubMedCentralGoogle Scholar
  211. Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ (2013) Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS One 8(1):e53733PubMedPubMedCentralCrossRefGoogle Scholar
  212. Mahmood MN, Lee MW, Linden MD, Nathanson S, Hornyak TJ, Zarbo RJ (2002) Diagnostic value of HMB-45 and anti-Melan A staining of sentinel lymph nodes with isolated positive cells. Mod Pathol 15(12):1288PubMedCrossRefPubMedCentralGoogle Scholar
  213. Maiuri F, D’Andrea F, Gallicchio B, Carandente M (1985) Intracranial hemorrhages in metastatic brain tumors. J Neurosurg Sci 29(1):37–41PubMedPubMedCentralGoogle Scholar
  214. Majeski J (1999) Bilateral breast masses as initial presentation of widely metastatic melanoma. J Surg Oncol 72(3):175–177PubMedCrossRefPubMedCentralGoogle Scholar
  215. Malouf JF, Thompson RC, Maples WJ, Wolfe JT (1996) Diagnosis of right atrial metastatic melanoma by transesophageal echocardiographic-guided transvenous biopsy. Mayo Clin Proc 12:1167–1170. ElsevierCrossRefGoogle Scholar
  216. Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18(22):3782–3793PubMedCrossRefPubMedCentralGoogle Scholar
  217. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, Sosman JA, Lee RJ, Nolop K, Flaherty KT (2012) Marked, homogeneous, and early [18F] fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 30(14):1628–1634PubMedPubMedCentralCrossRefGoogle Scholar
  218. McCarthy WH, Shaw HM, Thompson JF, Milton GW (1988) Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 166(6):497–502PubMedPubMedCentralGoogle Scholar
  219. McCutcheon IE, Waguespack SG, Fuller GN, Couldwell WT (2007) Metastatic melanoma to the pituitary gland. Can J Neurol Sci 34(3):322–327PubMedCrossRefPubMedCentralGoogle Scholar
  220. McDermott V, Low V, Keogan MT, Lawrence J, Paulson EK (1996) Malignant melanoma metastatic to the gastrointestinal tract. AJR Am J Roentgenol 166(4):809–813PubMedCrossRefPubMedCentralGoogle Scholar
  221. Mehta M, Omer E (2017) Isolated metastatic melanoma to the pancreas diagnosed by endoscopic ultrasonography: a case report. J Pancreas 18(2):144–146Google Scholar
  222. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, Mascaró JM, Vives-Corrons JL, Grau JJ, Estapé J (1996) Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 14(7):2091–2097PubMedCrossRefPubMedCentralGoogle Scholar
  223. Mellado B, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, Estapé J (1999) Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 5(7):1843–1848PubMedGoogle Scholar
  224. Merimsky O, Inbar M, Chaitchik S (1992) Metastases to skeletal muscles and interferon treatment. Mol Biother 4(2):95–96PubMedPubMedCentralGoogle Scholar
  225. Meyer JE (1974) Metastatic melanoma of the urinary bladder. Cancer 34(5):1822–1824PubMedCrossRefGoogle Scholar
  226. Meyer I, Shklar G (1965) Malignant tumors metastatic to mouth and jaws. Oral Surg Oral Med Oral Pathol 20(3):350–362PubMedCrossRefGoogle Scholar
  227. Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D (2005) Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23(22):5088–5093PubMedCrossRefPubMedCentralGoogle Scholar
  228. Michie SA, Spagnolo DV, Dunn KA, Warnke RA, Rouse RV (1987) A panel approach to the evaluation of the sensitivity and specificity of antibodies for the diagnosis of routinely processed histologically undifferentiated human neoplasms. Am J Clin Pathol 88(4):457–462PubMedCrossRefPubMedCentralGoogle Scholar
  229. Miliotes G, Lyman GH, Cruse CW, Puleo C, Albertini J, Rapaport D, Glass F, Fenske N, Soriano T, Cuny C (1996) Evaluation of new putative tumor markers for melanoma. Ann Surg Oncol 3(6):558–563PubMedCrossRefPubMedCentralGoogle Scholar
  230. Miranda EP, Gertner M, Wall J, Grace E, Kashani-Sabet M, Allen R, Leong SP (2004) Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 139(8):831–837PubMedCrossRefGoogle Scholar
  231. Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE (2008) Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 195(3):363–369PubMedCrossRefGoogle Scholar
  232. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR (2006) The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res 12(15):4605–4613PubMedCrossRefGoogle Scholar
  233. Mohamed A, Gonzalez RS, Lawson D, Wang J, Cohen C (2013) SOX10 expression in malignant melanoma, carcinoma, and normal tissues. Appl Immunohistochem Mol Morphol 21(6):506–510.  https://doi.org/10.1097/PAI.0b013e318279bc0aCrossRefPubMedGoogle Scholar
  234. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG (1997) Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences. Cancer 80(6):1052–1064PubMedCrossRefGoogle Scholar
  235. Mucci T, Long W, Witkiewicz A, Mastrangelo MJ, Rosato EL, Berger AC (2007) Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg 11(12):1755–1757PubMedCrossRefGoogle Scholar
  236. Munoz J, Vinolas N, Castro J, Graus F, Conde C, Castel T, Biete A, Tolosa E, Estapé J (1993) Cerebral metastasis of melanoma: study of 48 patients. Med Clin 101(18):684–687Google Scholar
  237. Murray JL (1983) Primary malignant melanoma metastatic to vitreous humor of the eye: treatment with BCNU. South Med J 76(4):523–526PubMedCrossRefGoogle Scholar
  238. Murray C, D’intino Y, MacCormick R, Nassar B, Walsh N (1999) Melanosis in association with metastatic malignant melanoma: report of a case and a unifying concept of pathogenesis. Am J Dermatopathol 21(1):28–30PubMedCrossRefGoogle Scholar
  239. Muss HB, Richards F 2nd, Barnes PL, Willard VV, Cowan RJ (1979) Radionuclide scanning in patients with advanced malignant melanoma. Clin Nucl Med 4(12):516–518PubMedCrossRefGoogle Scholar
  240. Myall RW, Morton TH, Worthington P (1983) Melanoma metastatic to the mandible: report of a case. Int J Oral Surg 12(1):56–59PubMedCrossRefGoogle Scholar
  241. Nakazono M, Iwata S, Kuribayashi N (1975) Disseminated metastatic ureteral melanoma: a case report. J Urol 114(4):624–625PubMedCrossRefGoogle Scholar
  242. Nambisan RN, Alexiou G, Reese PA, Karakousis CP (1987) Early metastatic patterns and survival in malignant melanoma. J Surg Oncol 34(4):248–252PubMedCrossRefGoogle Scholar
  243. Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG (2007) Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 14(10):2847–2853PubMedCrossRefGoogle Scholar
  244. Neuman HB, Patel A, Ishill N, Hanlon C, Brady MS, Halpern AC, Houghton A, Coit DG (2008) A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol 15(7):2034–2041PubMedCrossRefGoogle Scholar
  245. Nguyen NC, Chaar BT, Osman MM (2007) Prevalence and patterns of soft tissue metastasis: detection with true whole-body F-18 FDG PET/CT. BMC Med Imaging 7(1):8PubMedPubMedCentralCrossRefGoogle Scholar
  246. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H (2002) Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21(46):7001PubMedCrossRefGoogle Scholar
  247. Ordóñez N, Sneige N, Hickey R, Brooks T (1988a) Use of monoclonal antibody HMB-45 in the cytologic diagnosis of melanoma. Acta Cytol 32(5):684–688PubMedGoogle Scholar
  248. Ordóñez NG, Xiaolong J, Hickey RC (1988b) Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 90(4):385–390PubMedCrossRefGoogle Scholar
  249. Paquin AJ, Roland SI (1956) Secondary carcinoma of the penis. A review of the literature and a report of nine new cases. Cancer 9(3):626–632PubMedCrossRefGoogle Scholar
  250. Park TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, Morton KE, White DE, Rosenberg SA, Sherry RM (2017) Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol 24(4):947–951PubMedPubMedCentralCrossRefGoogle Scholar
  251. Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135(6):807–810PubMedCrossRefGoogle Scholar
  252. Patel K, Ward S, Packer T, Brown S, Marsden J, Thomson M, Ismail T (2014) Malignant melanoma of the gastro-intestinal tract: a case series. Int J Surg 12(5):523–527PubMedCrossRefGoogle Scholar
  253. Paulus D, Libshitz H (1982) Metastasis to the breast. Radiol Clin N Am 20(3):561–568PubMedGoogle Scholar
  254. Pennington D, Milton G (1975) Cerebral metastasis from melanoma. ANZ J Surg 45(4):405–409CrossRefGoogle Scholar
  255. Petersen RP, Hanish SI, Haney JC, Miller CC, Burfeind WR, Tyler DS, Seigler HF, Wolfe W, D’Amico TA, Harpole DH (2007) Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 133(1):104–110.e102PubMedCrossRefGoogle Scholar
  256. Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, Garbe C, Brechtel K, Vonthein R, Bares R (2007) Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 43(3):557–564PubMedCrossRefGoogle Scholar
  257. Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, Selby P (1996) Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 7(3):297–301PubMedCrossRefGoogle Scholar
  258. Plaza JA, Perez-Montiel D, Mayerson J, Morrison C, Suster S (2008) Metastases to soft tissue. Cancer 112(1):193–203PubMedCrossRefGoogle Scholar
  259. Pliskin ME, Mastrangelo MJ, Brown AM, Custer RP (1976) Metastatic melanoma of the maxilla presenting as a gingival swelling. Oral Surg Oral Med Oral Pathol 41(1):101–104PubMedCrossRefGoogle Scholar
  260. Poo-Hwu WJ, Ariyan S, Lamb L, Papac R, Zelterman D, Hu GL, Brown J, Fischer D, Bolognia J, Buzaid AC (1999) Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86(11):2252–2258PubMedCrossRefGoogle Scholar
  261. Prakoso E, Selby WS (2007) Capsule endoscopy in patients with malignant melanoma. Am J Gastroenterol 102(6):1204PubMedCrossRefGoogle Scholar
  262. Pressman PI (1973) Malignant melanoma and the breast. Cancer 31(4):784–788PubMedCrossRefGoogle Scholar
  263. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF, Brunt LM (2007) Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 142(4):497–504PubMedCrossRefGoogle Scholar
  264. Rajaratnam A, Waugh J (2005) Adrenal metastases of malignant melanoma: characteristic computed tomography appearances. J Med Imaging Radiat Oncol 49(4):325–329Google Scholar
  265. Rappeport E, Loft A, Berthelsen A, Von Der Recke P, Noergaard Larsen P, Mellon Mogensen A, Wettergren A, Rasmussen A, Hillingsoe J, Kirkegaard P (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48(4):369–378PubMedCrossRefGoogle Scholar
  266. Reccia I, Pisanu A, Podda M, Uccheddu A (2015) An uncommon presentation of metastatic melanoma: a case report. Medicine 94(7):e319PubMedPubMedCentralCrossRefGoogle Scholar
  267. Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, Roedel R, Strunk H, Bieber T, Biersack H-J (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24(7):1178–1187PubMedCrossRefGoogle Scholar
  268. Reinhold U, Lüdtke-Handjery H-C, Schnautz S, Kreysel H-W, Abken H (1997) The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Investig Dermatol 108(2):166PubMedCrossRefGoogle Scholar
  269. Reintgen D, Thompson W, Garbutt J, Seigler H (1984) Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery 95(6):635–639PubMedGoogle Scholar
  270. Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF (1992) Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 28(1):45–49PubMedCrossRefGoogle Scholar
  271. Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS (2018) Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol 36(17):1668–1674.  https://doi.org/10.1200/JCO.2017.75.6270CrossRefPubMedGoogle Scholar
  272. Robertson DM, Wilkinson CP, Murray JL, Gordy DD (1981) Metastatic tumor to the retina and vitreous cavity from primary melanoma of the skin: treatment with systemic and subconjunctival chemotherapy. Ophthalmology 88(12):1296–1301PubMedCrossRefGoogle Scholar
  273. Rodrigues LK, Leong SP, Ljung B-M, Sagebiel RW, Burnside N, Hu TI, Ng BW, Miller JR, Kashani-Sabet M (2000) Fine needle aspiration in the diagnosis of metastatic melanoma. J Am Acad Dermatol 42(5):735–740PubMedCrossRefGoogle Scholar
  274. Roelcke U, Leenders KL (2001) PET in neuro-oncology. J Cancer Res Clin Oncol 127(1):2–8PubMedCrossRefGoogle Scholar
  275. Rolz-Cruz G, Kim CC (2008) Tumor invasion of the skin. Dermatol Clin 26(1):89–102PubMedCrossRefGoogle Scholar
  276. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB (2010) Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 28(18):3042–3047.  https://doi.org/10.1200/JCO.2009.26.2063CrossRefPubMedPubMedCentralGoogle Scholar
  277. Romero JB, Stefanato CM, Kopf AW, Bart RS (1994) Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol 20(3):175–178PubMedCrossRefGoogle Scholar
  278. Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC (2015) Predictive value of early 18 F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging 42(3):386–396PubMedCrossRefGoogle Scholar
  279. Saha S, Meyer M, Krementz ET, Hoda S, Carter RD, Muchmore J, Sutherland C (1994) Prognostic evaluation of intracranial metastasis in malignant melanoma. Ann Surg Oncol 1(1):38–44PubMedCrossRefGoogle Scholar
  280. Samit A, Falk H, Ohanian M, Leban S, Mashberg A (1978) Malignant melanoma metastatic to the mandible. J Oral Surg (American Dental Association: 1965) 36(10):816–821Google Scholar
  281. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11–20PubMedCrossRefGoogle Scholar
  282. Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, Martin AM (2016) Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clin Cancer Res 22(3):567–574.  https://doi.org/10.1158/1078-0432.CCR-15-0321CrossRefPubMedGoogle Scholar
  283. Savoia P, Fierro MT, Zaccagna A, Bernengo MG (2000) Metastatic melanoma of the heart. J Surg Oncol 75(3):203–207PubMedCrossRefGoogle Scholar
  284. Sbitti Y, Fadoukhair Z, Kadiri H, Oukabli M, Essaidi I, Kharmoum S, M'rabti H, Albouzidi A, Ichou M, Errihani H (2011) Diagnostic challenge for ovarian malignant melanoma in premenopausal women: primary or metastatic? World J Surg Oncol 9(1):65PubMedPubMedCentralCrossRefGoogle Scholar
  285. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet.  https://doi.org/10.1016/S0140-6736(17)31601-XCrossRefGoogle Scholar
  286. Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandala M, Haanen J, Lebbe C, Mackiewicz A, Rutkowski P, Grob JJ, Nathan P, Ribas A, Davies MA, Zhang Y, Kaper M, Mookerjee B, Legos JJ, Flaherty KT, Robert C (2017) Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 82:45–55.  https://doi.org/10.1016/j.ejca.2017.05.033CrossRefPubMedGoogle Scholar
  287. Schaefer-Hesterberg G, Van Akkooi AJ, Letsch A, Roewert J, Blume-Peytavi U, Keilholz U, Christiane V (2011) Clinically misinterpreted melanoma metastases can correctly be diagnosed by ultrasound-guided fine needle aspiration cytology. Eur J Dermatol 21(2):238–241PubMedGoogle Scholar
  288. Schäfer-Hesterberg G, Schoengen A, Sterry W, Voit C (2007) Use of ultrasound to early identify, diagnose and localize metastases in melanoma patients. Expert Rev Anticancer Ther 7(12):1707–1716PubMedCrossRefGoogle Scholar
  289. Scheibenbogen C, Möhler T, Haefele J, Hunstein W, Keilholz U (1995) Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 5(3):179–181PubMedCrossRefGoogle Scholar
  290. Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Schwarz M, Rassner G, Garbe C (2000) Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res 10(5):451–459PubMedCrossRefGoogle Scholar
  291. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H (2006a) Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5):1130–1139PubMedCrossRefGoogle Scholar
  292. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, Larsen J, von der Maase H (2006b) Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol 24(5):798–804PubMedCrossRefGoogle Scholar
  293. Schneider A, Martini N, Burt ME (1993) Malignant melanoma metastatic to the esophagus. Ann Thorac Surg 55(2):516–517PubMedCrossRefGoogle Scholar
  294. Schneider B, Zienkiewicz T, Langenstein B, Vierbuchen M, Meinertz T (1994) Metastatic malignant melanoma initially seen as congestive heart failure: diagnosis by transesophageal echocardiography. Am Heart J 128(2):414–416PubMedCrossRefGoogle Scholar
  295. Schüle S-C, Eigentler TK, Garbe C, La Fougère C, Nikolaou K, Pfannenberg C (2016) Influence of 18 F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. Eur J Nucl Med Mol Imaging 43(3):482–488PubMedCrossRefGoogle Scholar
  296. Schultz S, Kane M, Roush R, Miller V, Berd D, Goldman L, Mastrangelo M (1990) Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma. Surg Gynecol Obstet 171(5):393–397PubMedPubMedCentralGoogle Scholar
  297. Schwartz RA (1995) Cutaneous metastatic disease. J Am Acad Dermatol 33(2):161–185PubMedCrossRefPubMedCentralGoogle Scholar
  298. Schwimmer J, Essner R, Patel A, Jahan S (2000) A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med Mol Imaging 44(2):153Google Scholar
  299. Seidenwurm DJ, Elmer EB, Kaplan LM, Williams EK, Morris DG, Hoffman AR (1984) Metastases to the adrenal glands and the development of Addison’s disease. Cancer 54(3):552–557PubMedCrossRefPubMedCentralGoogle Scholar
  300. Sen CA, Kargi A, Kaya V, Tanriverdi O (2013) Isolated and solitary splenic metastasis detected by positron emission tomography in a patient with malignant melanoma: case report and review of the literature. Contemp Oncol 17(2):214Google Scholar
  301. Shakhova O, Zingg D, Schaefer SM, Hari L, Civenni G, Blunschi J, Claudinot S, Okoniewski M, Beermann F, Mihic-Probst D, Moch H, Wegner M, Dummer R, Barrandon Y, Cinelli P, Sommer L (2012) Sox10 promotes the formation and maintenance of giant congenital naevi and melanoma. Nat Cell Biol 14(8):882–890.  https://doi.org/10.1038/ncb2535CrossRefPubMedPubMedCentralGoogle Scholar
  302. Sheldon R, Isaac D (1991) Metastatic melanoma to the heart presenting with ventricular tachycardia. Chest 99(5):1296–1298PubMedCrossRefPubMedCentralGoogle Scholar
  303. Shenberger K, Morgan JG (1982) Recurrent malignant melanoma presenting as monoarthritis. J Rheumatol 9(2):328–330PubMedPubMedCentralGoogle Scholar
  304. Shimko MS, Jacobs SC, Phelan MW (2007) Renal metastasis of malignant melanoma with unknown primary. Urology 69(2):384.e389–384.e310CrossRefGoogle Scholar
  305. Silberberg I, Kopf AW, Gumport SL (1968) Diffuse melanosis in malignant melanoma: report of a case and of studies by light and electron microscopy. Arch Dermatol 97(6):671–677PubMedCrossRefPubMedCentralGoogle Scholar
  306. Silveira E, Palhares FAB, de Oliveira Filho JA, Alberti O Jr, Alberti VN, Silveira MIG (1977) Peritonitis following rupture of metastatic malignant melanoma of the ovary. Gynecol Oncol 5(3):305–307PubMedCrossRefPubMedCentralGoogle Scholar
  307. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10):3091–3098PubMedCrossRefPubMedCentralGoogle Scholar
  308. Skibber JM, Soong S-J, Austin L, Balch CM, Sawaya RE (1996) Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3(2):118–123PubMedCrossRefPubMedCentralGoogle Scholar
  309. Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA (2018) Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer 124(2):297–305PubMedCrossRefPubMedCentralGoogle Scholar
  310. Smit L, Korse C, Bonfrer J (2005) Comparison of four different assays for determination of serum S-100B. Int J Biol Markers 20(1):34–42PubMedCrossRefPubMedCentralGoogle Scholar
  311. Smith GW, Griffith D, Pranke DW (1973) Melanospermia: an unusual presentation of malignant melanoma. J Urol 110(3):314–316PubMedCrossRefPubMedCentralGoogle Scholar
  312. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair G (1991) Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338(8777):1227–1229PubMedCrossRefPubMedCentralGoogle Scholar
  313. Smoller BR, McNutt NS, Hsu A (1989) HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma. Am J Surg Pathol 13(8):680–684PubMedCrossRefPubMedCentralGoogle Scholar
  314. Sood S, Nair S, Fenwick J, Horgan K (1999) Metastatic melanoma of the tonsil. J Laryngol Otol 113(11):1036–1038PubMedCrossRefPubMedCentralGoogle Scholar
  315. Spiegel DA, Sampson JH, Richardson WJ, Friedman AH, Rossitch E, Hardaker WT Jr, Seigler HF (1995) Metastatic melanoma to the spine. Demographics, risk factors, and prognosis in 114 patients. Spine 20(19):2141–2146PubMedCrossRefPubMedCentralGoogle Scholar
  316. Spremulli EN, Bogaars HA, Dexter DL, Matook GM, Jolly GA, Kuhn RE, Cummings FJ, Calabresi P (1983) Nude mouse model of the melanosis syndrome. J Natl Cancer Inst 71(5):933–939PubMedPubMedCentralGoogle Scholar
  317. Srinivasan B, Patel M, Ethunandan M, Ilankovan V (2016) Addison’s disease as a presentation of metastatic malignant melanoma. Ann R Coll Surg Engl 98(1):e11–e12PubMedPubMedCentralCrossRefGoogle Scholar
  318. Srivatsa S, Rhee MK (2009) Metastatic melanoma presenting as a thyroid nodule in a 38-year-old woman. Hosp Physician 45:39–41Google Scholar
  319. Steiner A, Rappersberger K, Groh V, Pehamberger H (1991) Diffuse melanosis in metastatic malignant melanoma. J Am Acad Dermatol 24(4):625–628PubMedCrossRefPubMedCentralGoogle Scholar
  320. Steinert HC, Huch Böni R, Buck A, Böni R, Berthold T, Marincek B, Burg G, Von Schulthess G (1995) Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-d-glucose. Radiology 195(3):705–709PubMedCrossRefPubMedCentralGoogle Scholar
  321. Stewart W, Gelberman R, Harrelson J, Seigler H (1978) Skeletal metastases of melanoma. J Bone Joint Surg Am 60(5):645–649PubMedCrossRefPubMedCentralGoogle Scholar
  322. Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC (2007a) High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 244(2):566–574PubMedCrossRefPubMedCentralGoogle Scholar
  323. Strobel K, Skalsky J, Steinert HC, Dummer R, Hany TF, Bhure U, Seifert B, Lago MP, Joller-Jemelka H, Kalff V (2007b) S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 215(3):192–201PubMedCrossRefPubMedCentralGoogle Scholar
  324. Strobel K, Dummer R, Steinert HC, Conzett KB, Schad K, Lago MP, Soyka JD, Veit-Haibach P, Seifert B, Kalff V (2008) Chemotherapy response assessment in stage IV melanoma patients – comparison of 18 F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging 35(10):1786PubMedCrossRefPubMedCentralGoogle Scholar
  325. Stroup RM, Pinkus GS (1988) S-100 immunoreactivity in primary and metastatic carcinoma of the breast: a potential source of error in immunodiagnosis. Hum Pathol 19(8):949–953PubMedCrossRefPubMedCentralGoogle Scholar
  326. Stryga M, Janas M, Szopiński P (2009) Melanoma metastases to the small intestine mesentery, greater omentum and parietal peritoneum-case report. Pol J Surg 81(4):203–207Google Scholar
  327. Sze G, Soletsky S, Bronen R, Krol G (1989) MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. Am J Roentgenol 153(5):1039–1049CrossRefGoogle Scholar
  328. Taback B, Morton D, O’day S, Nguyen D-H, Nakayama T, Hoon D (2001) The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. In: Minimal residual disease in melanoma. Springer, Berlin, pp 78–92CrossRefGoogle Scholar
  329. Takeda M, Diamond S, DeMarco M, Quinn D (1978) Cytologic diagnosis of malignant melanoma metastatic to the endometrium. Acta Cytol 22(6):503–506PubMedPubMedCentralGoogle Scholar
  330. Tarhini AA, Stuckert J, Lee S, Sander C, Kirkwood JM (2009) Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694. J Clin Oncol 27(1):38–44PubMedPubMedCentralCrossRefGoogle Scholar
  331. Ten Bokkel Huinink DT, Veltman GA, Huizinga TW, Roelfsema F, Keizer HJ (2000) Diabetes insipidus in metastatic cancer: two case reports with review of the literature. Ann Oncol 11(7):891–895.  https://doi.org/10.1023/A:1008319027651CrossRefGoogle Scholar
  332. Tessier DJ, McConnell EJ, Young-Fadok T, Wolff BG (2003) Melanoma metastatic to the colon: case series and review of the literature with outcome analysis. Dis Colon Rectum 46(4):441–447.  https://doi.org/10.1097/01.dcr.0000059657.64526.b6CrossRefPubMedPubMedCentralGoogle Scholar
  333. Tolley DA, Castro JE, Ansell ID (1975) Malignant metastatic melanoma of the bladder. Br J Clin Pract 29(10):276–278PubMedPubMedCentralGoogle Scholar
  334. Torizuka T, Zasadny KR, Recker B, Wahl RL (1998) Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 207(3):767–774PubMedCrossRefPubMedCentralGoogle Scholar
  335. Tse CS, Tan N, Idossa D, Click R (2017) Cardiac melanoma: retrospective review of a rare disease at the Mayo clinic (1988–2015). Int J Cardiol 249:383–386PubMedCrossRefPubMedCentralGoogle Scholar
  336. Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, Fisher S, Coleman E, Seigler HF (2000) Positron emission tomography scanning in malignant melanoma. Cancer 89(5):1019–1025PubMedCrossRefPubMedCentralGoogle Scholar
  337. Ulbright TM, Roth LM, Stehman FB (1984) Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. Cancer 53(5):1164–1174PubMedCrossRefPubMedCentralGoogle Scholar
  338. Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK (2001) Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 91(6):1148–1155PubMedCrossRefPubMedCentralGoogle Scholar
  339. Utikal J, Schadendorf D, Ugurel S (2007) Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies. Arch Dermatol Res 298(10):469–477PubMedPubMedCentralCrossRefGoogle Scholar
  340. Vida L, Binder P (1978) Simultaneous metastasis of skin melanoma to the eye and orbit. Ann Ophthalmol 10(4):431–433PubMedPubMedCentralGoogle Scholar
  341. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G (2001) FDG–PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 77(4):237–242PubMedCrossRefPubMedCentralGoogle Scholar
  342. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossman HB, Fisher S (1991) 18F-2-deoxy-2-fluoro-d-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography. Cancer 67(6):1544–1550PubMedCrossRefPubMedCentralGoogle Scholar
  343. Waller BF, Gottdiener JS, Virmani R, Roberts WC (1980) The “charcoal heart”: melanoma to the cor. Chest 77(5):671–676PubMedCrossRefPubMedCentralGoogle Scholar
  344. Walts AE, Said JW, Shintaku IP (1988) Cytodiagnosis of malignant melanoma: immunoperoxidase staining with HMB-45 antibody as an aid to diagnosis. Am J Clin Pathol 90(1):77–80PubMedCrossRefPubMedCentralGoogle Scholar
  345. Wasserstrom WR, Glass JP, Posner JB (1982) Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49(4):759–772PubMedCrossRefPubMedCentralGoogle Scholar
  346. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22:5487PubMedPubMedCentralCrossRefGoogle Scholar
  347. Weisberg LA (1985) Hemorrhagic metastatic intracranial neoplasms: clinical-computed tomographic correlations. Comput Radiol 9(2):105–114PubMedCrossRefGoogle Scholar
  348. Weiss M, Loprinzi CL, Creagan ET, Dalton R, Novotny P, O’fallon JR (1995) Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. Jama 274(21):1703–1705PubMedCrossRefPubMedCentralGoogle Scholar
  349. Welch RD, Hirsch SA, Davis RG (1985) Melanoma with metastasis to an apical periodontal cyst. Oral Surg Oral Med Oral Pathol 59(2):189–193PubMedCrossRefPubMedCentralGoogle Scholar
  350. Willis BC, Johnson G, Wang J, Cohen C (2015) SOX10: a useful marker for identifying metastatic melanoma in sentinel lymph nodes. Appl Immunohistochem Mol Morphol 23(2):109–112.  https://doi.org/10.1097/PAI.0000000000000097CrossRefPubMedPubMedCentralGoogle Scholar
  351. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res.  https://doi.org/10.1158/1078-0432.CCR-09-1624PubMedCrossRefGoogle Scholar
  352. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med.  https://doi.org/10.1056/NEJMoa1709684PubMedCrossRefGoogle Scholar
  353. Wong AN, McArthur GA, Hofman MS, Hicks RJ (2017) The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging 44(1):67–77PubMedCrossRefGoogle Scholar
  354. Wood M, Donegan J (1983) Metastatic melanoma to the palatine tonsil. Ear Nose Throat J 62(10):62, 64PubMedGoogle Scholar
  355. Wood C, Wood R (1975) Metastatic malignant melanoma of the esophagus. Am J Dig Dis 20(8):786–789PubMedCrossRefGoogle Scholar
  356. Woodard B, Ideker R, Johnston W (1978) Cytologic detection of malignant melanoma in urine. A case report. Acta Cytol 22(5):350–352PubMedGoogle Scholar
  357. Xie T-x, Huang F-J, Aldape KD, Kang S-H, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S (2006) Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res 66(6):3188–3196PubMedCrossRefGoogle Scholar
  358. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN (2011) Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103(2):129–142PubMedPubMedCentralCrossRefGoogle Scholar
  359. Yeung K-Y, Bonnet JD (1977) Spontaneous pneumothorax with metastatic malignant melanoma. Chest 71(3):435–436PubMedCrossRefGoogle Scholar
  360. Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P (2018) Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 18(1):130.  https://doi.org/10.1186/s12885-018-4016-3CrossRefPubMedPubMedCentralGoogle Scholar
  361. Zakka KA, Foos RY, Omphroy CA, Straatsma BR (1980) Malignant melanoma: analysis of an autopsy population. Ophthalmology 87(6):549–556PubMedCrossRefGoogle Scholar
  362. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, Shapiro R, Berman R, Darvishian F, Hernando E (2011) Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer 117(8):1711–1720PubMedCrossRefGoogle Scholar
  363. Zegarelli DJ, Tsukada Y, Pickren JW, Greene GW (1973) Metastatic tumor to the tongue: report of twelve cases. Oral Surg Oral Med Oral Pathol Oral Radiol 35(2):202–211CrossRefGoogle Scholar
  364. Zekri J, Marples M, Taylor D, Kandukurti K, McParland L, Brown JE (2017) Complications of bone metastases from malignant melanoma. J Bone Oncol 8:13–17PubMedPubMedCentralCrossRefGoogle Scholar
  365. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2):384–394PubMedCrossRefGoogle Scholar
  366. Zitzelsberger T, Eigentler TK, Krumm P, Nikolaou K, Garbe C, Gawaz M, Klumpp B (2017) Imaging characteristics of cardiac metastases in patients with malignant melanoma. Cancer Imaging 17(1):19PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ahmad A. Tarhini
    • 1
    Email author
  • Sanjiv S. Agarwala
    • 2
  • Arjun Khunger
    • 3
  • Richard L. Wahl
    • 4
  • Charles M. Balch
    • 5
  1. 1.Department of Hematology and Medical OncologyEmory University School of Medicine, Winship Comprehensive Cancer CenterAtlantaUSA
  2. 2.Department of Medical OncologySt Luke’s University Hospital and Health NetworkEastonUSA
  3. 3.Department of Hematology and OncologyTaussig Cancer Center, Cleveland ClinicClevelandUSA
  4. 4.Mallinckrodt Institute of RadiologyWashington University School of MedicineSt. LouisUSA
  5. 5.Department of Surgical OncologyUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations